Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00209989 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study Status, Referencesv9
  2. Primary and study completion dates changed from estimate of Sep 2010 to Jun 2011 Trial status: Active, Not Recruiting to Completedv8 Show 1 more changeShow less
    • Trial status: Active, Not Recruiting to Completed
  3. Trial status: Recruiting to Active, Not Recruiting Primary completion date: Sep 2010 · Completion date: Dec 2008 to Sep 2010 · Site details revised at 2 of 2 sitesv7 Show 3 more changesShow less
    • Primary completion date: Sep 2010
    • Completion date: Dec 2008 to Sep 2010
    • Site details revised at 2 of 2 sites
  4. Completion date: Dec 2007 to Dec 2008 Secondary endpoints: details revised at 3 of 3 entriesv6 Show 1 more changeShow less
    • Secondary endpoints: details revised at 3 of 3 entries
  5. Completion date: Jun 2006 to Dec 2007 Site contacts updated at 1 of 2 sitesv5 Show 1 more changeShow less
    • Site contacts updated at 1 of 2 sites
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites: 1 to 2 Collaborators expanded, about 2 wordsv4 Show 1 more changeShow less
    • Collaborators expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Eligibility criteria expanded, about 1 wordv3 See this version in full on ClinicalTrials.gov ↗
  3. Trial status: Not Yet Recruiting to Recruiting Start date: Oct 2005 · Site details revisedv2 Show 2 more changesShow less
    • Start date: Oct 2005
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine the efficacy by the determination of the Time To Progression (TTP) in patients with resectable GBM or non surgical GBM with a size less than 5 cm treated with the combination of ZARNESTRA plus Radiation therapy.
Trial Details
NCT Number NCT00209989
Lead Sponsor Institut Claudius Regaud
Collaborators: Janssen-Cilag Ltd.
Conditions Glioblastoma Multiforme
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov